DOCSLIB.ORG

Tympanostomy Tubes in Children with Otitis Media

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tympanostomy Tubes in Children with Otitis Media Comparative Effectiveness Review Number 185 Tympanostomy Tubes in Children With Otitis Media e Comparative Effectiveness Review Number 185 Tympanostomy Tubes in Children With Otitis Media Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00002-I Prepared by: Brown Evidence-based Practice Center Providence, RI Investigators: Dale Steele, M.D., M.S. Gaelen P. Adam, M.L.I.S. Mengyang Di, M.D., Ph.D. Christopher Halladay, B.A., Sc.M. Ian Pan, M.A. Nathan Coppersmith, B.A. Ethan M. Balk, M.D., M.P.H. Thomas A. Trikalinos, M.D., Ph.D. AHRQ Publication 17-EHC003-EF May 2017 This report is based on research conducted by the Brown Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00002-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders. AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact [email protected]. Suggested citation: Steel D, Adam GP, Di M, Halladay C, Pan I, Coppersmith N, Balk EM, Trikalinos TA. Tympanostomy Tubes in Children With Otitis Media. Comparative Effectiveness Review No. 185. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I.) AHRQ Publication No. 17-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2017. www.effectivehealthcare.ahrq.gov/reports/final.cfm. doi: https://doi.org/10.23970/AHRQEPCCER185. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm. AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. If you have comments on this systematic review, they may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to [email protected]. Sharon B. Arnold, Ph.D. Arlene S. Bierman, M.D., M.S. Acting Director Director Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. Lionel L. Bañez, M.D. Director Task Order Officer Evidence-based Practice Center Program Center for Evidence and Practice Improvement Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Key Informants In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants. Key Informants must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest. The list of Key Informants who provided input to this report follows: Margaretha Casselbrandt, M.D., Ph.D.* Alison Kelly, B.S.N., R.N., C.P.E.N. Department of Pediatric Otolaryngology Hasbro Children’s Hospital Children's Hospital of Pittsburgh Providence, RI Pittsburgh, PA Josiah Morse, M.P.H. Alison Grimes, Au.D.* Washington State Health Technology Audiology Department Assessment Program UCLA Medical Center Olympia, WA Los Angeles, CA Richard Rosenfeld, M.D., M.P.H., FAAP* David Hoelting, M.D. Department of Otolaryngology Pender Medical Clinic SUNY Downstate Medical Center Pender Community Hospital Brooklyn, NY Pender, NE David E. Tunkel, M.D.* Director of Pediatric Otolaryngology Johns Hopkins University School of Medicine Baltimore, MD *Provided input on draft report. Technical Expert Panel In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts. Technical Experts must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified. iv The list of Technical Experts who provided input to this report follows: Alison Grimes, Au.D.* Richard Rosenfeld, M.D., M.P.H., FAAP* Audiology Department Department of Otolaryngology UCLA Medical Center SUNY Downstate Medical Center Los Angeles, CA Brooklyn, NY David Hoelting, M.D. Lorry Rubin, MD* Pender Medical Clinic Hofstra North Shore-LIJ School of Medicine Pender Community Hospital Hempstead, NY Pender, NE David E. Tunkel, M.D.* Howard J. Hoffman, B.S., M.A.* Director of Pediatric Otolaryngology Epidemiology and Statistics Program Johns Hopkins University School of Medicine Division of Scientific Programs Baltimore, MD National Institute on Deafness and Other Communication Disorders Roderick Venekamp, M.D., M.Sc., Ph.D.* National Institutes of Health University Medical Center Utrecht U.S. Department of Health and Human Services Julius Center for Health Sciences and Primary Bethesda, MD Care & Department of Otorhinolaryngology The Netherlands *Provided input on draft report. v Peer Reviewers Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers.
Load more

Recommended publications
  • 7.01.158 Balloon Dilation of the Eustachian Tube
    MEDICAL POLICY – 7.01.158 Balloon Dilation of the Eustachian Tube BCBSA Ref. Policy: 7.01.158 Effective Date: Dec. 1, 2020 RELATED MEDICAL POLICIES: Last Revised: Nov. 10, 2020 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction The eustachian tube is a small, hollow structure that connects the middle ear to the back of the nose. Each ear has a eustachian tube, which is usually filled with air. Its function is to keep pressure inside the ear the same as the pressure outside of the body. It does this by opening and closing, like a valve. These are the tubes that open as a person swallows or yawns, and that make your ears “pop” when you change altitude. If one or both tubes aren’t able to open and close properly, this can lead to symptoms like muffled hearing, a feeling of fullness in the ear, ringing in the ear (tinnitus), and feeling dizzy (vertigo). Over time, ongoing problems with the eustachian tube(s) can lead to inflammation, damage to the eardrum, and possible hearing loss. A technique has been developed in which a small tube containing a balloon is inserted into the nose and then threaded into the eustachian tube. The tiny balloon is then inflated, which opens the tube. The balloon is left in place for a couple of minutes, deflated, and removed. This policy discusses when this technique is considered medically necessary.
    [Show full text]
  • Long-Term Outcomes of a Single Institution's Tympanostomy Tube
    Long-term outcomes of a single institution’s tympanostomy tube protocol in children with cleft palate MaryRoz Timbang, MD1, Tsung-Yen Hsieh, MD1, Kate Ostedgaard, MD1, Samantha Nguyen1, Jamie Funamura, MD, MPH1, and Craig W Senders, MD, FACS1 1Department of Otolaryngology - Head and Neck Surgery, University of California, Davis BACKGROUND RESULTS RESULTS CONCLUSIONS • Tympanostomy tube insertion for children with cleft lip Table 1. Baseline Characteristics Figure 1. Summary of Findings by Ears at Ten-Year Follow-Up • Otologic complications at ten-year follow-up included 32 cases of and/or palate is often utilized as a prophylactic measure for myringosclerosis and 20 chronic perforations, but there were zero 140 otitis media with effusion in this at-risk group during a critical N (%/SD) Otologic Findings cases of cholesteatoma, a potential complication associated with time of speech and language development. Age at palate repair, years 1.14 (SD 0.47) 127 tympanostomy tube insertion in which cyst-like growths of epithelial tissue invade and dissolve ossicles in the middle ear or Male (%) 47 (50) 120 erode through the skull base and affect the brain. This reflects • Although eustachian tube dysfunction and susceptibility to the success of the surgeries at our institution in preventing this middle ear effusion is well established in this pediatric Cleft lip (%) 53 (56) feared complication of recurrent acute otitis media. population, controversy exists regarding the impact of early Ethnicity and routine versus selective tympanostomy tube placement on 100 Latino 32 • However, our institution’s protocol of routine short-term ear tube long-term hearing and language development.
    [Show full text]
  • Disease Staging Software™ Reference Guide
    Disease Staging Software™ Version 5.26 Reference Guide COPYRIGHT © 1999-2009 THOMSON REUTERS. ALL RIGHTS RESERVED. - 1 - Copyright © 1999-2009 Thomson Reuters. ALL RIGHTS RESERVED. MEDSTAT® Reg. U.S. Pat. & Tm. Off. All rights reserved. No part of this publication may be reproduced, translated or transmitted in any form, by photocopy, microfilm, xerography, recording or any other means, or stored or incorporated into any information retrieval system, electronic or mechanical, without the prior written permission of the copyright owner. Requests for permission to copy any part of this publication or for additional copies should be addressed to: Thomson Reuters 777 E. Eisenhower Pkwy. Ann Arbor, Michigan 48108. The software, data and other information to which this manual relates have been provided under the terms of a License Agreement with Thomson Reuters, Inc. All Thomson Reuters clients using Medstat Disease Staging Software® are required to obtain their own licenses for use of all applicable medical coding schemes including but not limited to: Major Diagnostic Categories (MDCs), Diagnosis Related Groups (DRGs), and ICD-9-CM. Trademarks: Medstat and Medstat Disease Staging Software are registered trademarks of Thomson Reuters, Inc. Intel and Pentium are registered trademarks of Intel Corporation. Microsoft, Windows, Windows NT, Windows 2000, and Windows XP are registered trademarks of Microsoft Corporation. SAS is a registered trademark of the SAS Institute, Inc. AIX and IBM are registered trademarks of the IBM Corporation. Sun and Solaris are trademarks or registered trademarks of Sun Microsystems, Inc. HP-UX is a registered trademark of the Hewlett-Packard Company. Linux® is the registered trademark of Linus Torvalds in the U.S.
    [Show full text]
  • Balloon Dilation of the Eustachian Tube: a Tympanometric Outcomes Analysis Blair Williams1, Benjamin A
    Williams et al. Journal of Otolaryngology - Head and Neck Surgery (2016) 45:13 DOI 10.1186/s40463-016-0126-6 ORIGINAL RESEARCH ARTICLE Open Access Balloon dilation of the eustachian tube: a tympanometric outcomes analysis Blair Williams1, Benjamin A. Taylor1, Neil Clifton2 and Manohar Bance1* Abstract Background: Eustachian tube dysfunction (ETD) is a common medical issue, occurring in at least 1 % of the adult population. Patients suffering from ET dysfunction typically present with complaints of hearing loss or sensation of pressure or plugged ear, which can lead to impaired quality of life. Over time ETD can result in conductive hearing loss or choleastatoma formation. Effective theraputic options for ET dysfunction are few. Eustachian tube balloon dilation is a novel surgical technique being used to treat ETD. The aim of our study is to objectively measure the success of Eustachian tube balloon dilation by comparing pre and post-operative middle ear pressures using tympanometric testing. Methods: RA retrospective chart review was preformed on all patients who underwent balloon dilation of the Eustachian tube by authors NC or MB from 2010 to 2014. Pre and post-operative tympanograms were analyzed and categorized based on type (Type A, Type B, Type C). Success was defined by an improvement in tympanogram type: Type B or C to Type A, or Type B to type C. Pre and post-operative tympanograms were further analyzed using middle ear pressure values. Follow-up ranged from 3 to 15 months. Results: Twenty-five ears (18 patients) were included in the study. Overall 36 % of ears had improvement in tympanogram type, and 32 % had normalization of tympanogram post-operatively.
    [Show full text]
  • Hyperbaric Oxygen Therapy (HBOT) Final Evidence Report
    20, 2012 Health Technology Assessment Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions Final Evidence Report February 15, 2013 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 hta.hca.wa.gov [email protected] Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – February 15, 2013 Acknowledgement This report was prepared by: Hayes, Inc. 157 S. Broad Street Suite 200 Lansdale, PA 19446 P: 215.855.0615 F: 215.855.5218 This report is intended to provide research assistance and general information only. It is not intended to be used as the sole basis for determining coverage policy or defining treatment protocols or medical modalities, nor should it be construed as providing medical advice regarding treatment of an individual’s specific case. Any decision regarding claims eligibility or benefits, or acquisition or use of a health technology is solely within the discretion of your organization. Hayes, Inc. assumes no responsibility or liability for such decisions. Hayes employees and contractors do not have material, professional, familial, or financial affiliations that create actual or potential conflicts of interest related to the preparation of this report. Prepared by Winifred Hayes, Inc. Page i February
    [Show full text]
  • Strand B, Rapid Assessment of Other Health Technologies Such As Medical Devices, Surgical Interventions Or Diagnostics
    333 EUnetHTA WP5 Joint Action 2 (2012-2015) Strand B, Rapid assessment of other health technologies such as medical devices, surgical interventions or diagnostics Pilot rapid assessment of other health technologies using the HTA Core Model® for Rapid Relative Effectiveness Assessment Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction Pilot ID: SB-13 Version 5.0, February, 2015 Final Version EUnetHTA JA2 Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction WP5B DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 26 August 2014 V1.0 = First draft V2.0 29 September 2014 Updated following review by dedicated reviewers V 3.0 13 November 2014 Updated version based on comments from external clinical experts, WP5 strand B members and manufacturers V 4.0 15 December 2014 Updated version based on the comments and corrections from medical editing V 5.0 3 February Updated version based on comments from LBI This assessment was produced by experts from the institutions listed below, and was reviewed by members of Work Package 5 (WP5) Joint Action 2 of the EUnetHTA network; the whole process was coordinated by the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA). Disclaimer The assessment represents a consolidated view of the EUnetHTA network members and is in no case the official opinion of the participating institutions or individuals. EUnetHTA Joint Action 2 is supported by a grant from the European Commission. The sole responsibility for the content of this document lies with the authors and neither the European Commission nor EUnetHTA are re- sponsible for any use that may be made of the information contained therein.
    [Show full text]
  • Criteria for Grommet Insertion in Adults: 1) Otitis Media with Effusion OME
    Bedfordshire and Hertfordshire INTERIM Priorities Forum Statement Number: 72 Subject: Grommet insertion in adults Date of decision: August 2016 Date of review: August 2017 GUIDANCE Criteria for grommet insertion in adults: 1) Otitis media with effusion OME that meets the following criteria: a) persisting after a prolonged period of watchful waiting/active observation of at least 4 months, (NB watchful waiting is not appropriate if malignancy suspected) b) there is a definitive diagnosis of OME and c) it persists; OR 2) Severe pain-due to air pressure changes when flying or in hyperbaric treatment. The severity and frequency of flying should be discussed with the patient and balanced against the possible complications associated with grommets; OR 3) Re-insertion of ventilation tubes- where its been inserted and fallen out- a 2nd or 3rd grommet may be inserted if they still meet one of the above criteria. NB Patients who do not meet the above criteria may be considered on an individual basis where the GP/Consultant believes exceptional circumstances may exist. In patients who suffer from subjective feelings of pressure or eustachian tube dysfunction-like symptoms, treatable underlying causes should be ruled out. Evidence Evidence for the use of grommets as a surgical intervention in otitis media with effusion. Most, if not all of the studies available relating to grommet insertion are actually studies conducted in children with hearing loss due to glue ear.. A systemic review by Mcdonald et al 2008 (looking at two studies) showed that grommets have a significant role in maintaining a disease free state in the first 6 months after insertion.
    [Show full text]
  • Petubes Patient Handout.Pdf
    Division of Pediatric Otolaryngology Information on Tympanostomy Tubes Tympanostomy tubes are small plastic or metal tubes that are placed into the tympanic membrane or ear drum. How long will the tube stay in place? Tubes usually fall out of the ear in 6 months- 2 years. If they remain in longer than 2 to 3 years they are sometimes removed. What is involved with Tympanostomy tube placement? This surgery is usually done under general anesthesia. The eardrum is examined using a microscope. A small hole is made in the ear drum called a myringotomy, fluid is removed, and the tube is placed. Tube in the eardrum What medical conditions are treated with tubes? Recurrent middle ear infections or frequent acute otitis media Otitis media with effusion or fluid in middle ear associated with hearing loss Eustachian tube dysfunction causing hearing loss or eardrum structure changes What is the Eustachian tube? This is the canal that links the middle ear with the throat. This tube allows air into the middle ear and drainage of fluid. This tube grows in width and length until children are about 5 years old. Reasons that the Eustachian tube may not work properly: Viral illness, exposure to allergens or tobacco smoke may lead to swelling of the eustachian tube resulting in fluid buildup in the middle ear. Children with cleft palate and craniofacial syndromes like Down’s syndrome may have poor eustachian tube function. How will Tympanostomy tube help my child? They allow air to re-enter middle ear space They reduce the number and severity of infections They improve hearing loss cause by middle ear fluid Why is adenoidectomy sometimes done with the Tympanostomy tubes? Adenoidectomy is the removal of the adenoid tissue behind the nose.
    [Show full text]
  • An Integrated Osteopathic Treatment Approach in Acute Otitis Media
    C A RF IC)RT S • An integrated osteopathic treatment approach in acute otitis media WILLIAM J. PINTAL, no MARGOT E. KURTZ, PhD Ear pain is a common patient pathogens, Streptococcus pneumoniae and Haemo- complaint in the practice of the primary philus influenzae, causative agents may include care physician. Acute otitis media can Streptococcus pyogenes, Staphylococcus aureus, My- affect a person of any age, although it is coplasma pneumoniae, and Corynebacterium diphth- more often seen in children than in adults. eriae. The disease is usually caused by Classically, the tympanic membrane is thick- Streptococcus pneumoniae (Diplococcus ened, and a gray or amber fluid is seen in the mid- pneumoniae) or Haemophilus influenzae. dle ear. Sometimes a fluid meniscus, air bubbles The differential diagnosis and subsequent of bluish fluid, may appear behind the tympanic treatment of otitis media is approximately membrane, the mobility of which is generally im- the same for children and adults. First-line paired. Depending on individual circumstances, the therapy usually consists of an antibiotic tympanic membrane may be either bulging or re- regimen of amoxicillin in combination with tracted. The bulging or retraction may result from autoinflation exercises. In the case the development of a positive or negative internal presented, a pharmacologic regimen was pressure, respectively, caused by dysfunction of the combined with osteopathic manipulation. eustachian tube. In the differential diagnosis, one must distin- guish between an acute purulent otitis media and In the course of caring for a wide range of pa- a serous or mucoid otitis media as well as between tients of different ages in a general practice–fam- the short-term perforation of the tympanic mem- ily medicine setting, one has the opportunity to care brane that is associated with acute purulent otitis for many ear infections.
    [Show full text]
  • Otovent Nasal Balloon for Otitis Media with Effusion
    pat hways Otovent nasal balloon for otitis media with effusion Medtech innovation briefing Published: 15 March 2016 www.nice.org.uk/guidance/mib59 Summary Otovent is a balloon device designed to relieve the symptoms of otitis media with effusion, commonly known as glue ear. An Otovent kit consists of a nose piece and 5 latex balloons that are inflated yb blowing through the nose. Four randomised controlled trials, all in children, have shown that using the device causes significant improvements, compared with standard care, in middle ear function; 1 of the trials also reported a significant reduction in the need for entilationv tube (grommet) insertion surgery. Outcomes varied by compliance with (that is, adherence to) treatment, and standard care was not consistently described. The Otovent kit is available to buy or can be provided on a NHS prescription. The recommended retail price is £7.84 including VAT and the current Drug Tariff price is £4.90 excluding VAT. No additional consumables are needed. © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 24 Otovent nasal balloon for otitis media with effusion (MIB59) Product summary and likely place in Effectiveness and safety therapy • No relevant evidence was found for the use of • Otovent is designed to help open the Otovent in adults. Eustachian tubes and equalise the air pressure in the middle ear. • Four randomised controlled trials involving a total of 565 children showed statistically significant • The device can be used in people improvements in middle ear function with with Eustachian tube dysfunction Otovent compared with standard care, as associated with glue ear (otitis determined by tympanometry and pneumatic media with effusion), or after flying, otometry.
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]
  • Tympanostomy Tube Placement © Ingenix, Inc
    Tympanostomy Tube Placement © Ingenix, Inc. 2011 Confidential Care Pattern CP-I 9000001 Patient(s) less than 12 years of age that had tympanostomy tube placement and met clinical criteria for this procedure. This document addresses tympanostomy tube placement in patients less than 12 years of age at the end of the report period. The earliest claim for tympanostomy tube placement was identified during the time period 365 days prior to the common report period end date. Patients with diagnosis for ear/nose/throat (ENT) congenital and acquired anomalies were excluded from this condition. Clinical indicators for tympanostomy tube placement have been developed by the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) (1). These clinical indicators include the following: hearing loss greater than 30 dB in patients with otitis media with effusion, poor response to antibiotic treatment for otitis media, otitis media with effusion greater than 3 months, recurrent episodes of acute otitis media (more than 3 episodes in 6 months or more than 4 episodes in 12 months), chronic retraction of the tympanic membrane or pars flaccida, barotitis media control, autophony due to patulous eustachian tube, craniofacial anomalies that predispose to middle ear dysfunction, or middle ear dysfunction due to head and neck radiation and skull base surgery. Based on these AAO-HNS clinical indicators and the consensus opinion of experts, a patient was adherent to this measure if one of the following clinical criteria was met: 1) three or more face-to-face
    [Show full text]